Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 3, 2014, Pages

  Ren, Shengxiang ^a   Hirsch, Fred R ^b   Varella Garcia, Marileila ^b   Aisner, Dara L ^b   Boyle, Theresa ^b   Zhou, Caicun ^a   Camidge, D Ross ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84894600245     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000013     Document Type: Article

References (5)

1. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.
2. Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, Camidge DR. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013;119:1467-1477.
3. Yoshida A, Tsuta K, Nitta H, et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-Associated protein-like 4-Anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011;6:1677-1686.
4. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-5590.
5. Peled N, Palmer G, Hirsch FR, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012;7(9):e14-16.